China Drug Delivery Market - Forecasts from 2024 to 2029

The China drug delivery market is projected to grow at a compound annual growth rate of 9.14% from a market value of US$76.071 billion in 2022 to US$140.356 billion in 2029. 

The growth is attributed to the rising number of market players in the pharmaceutical industry. The major pharma-dependent population is the age group above 64 years. Additionally, patients with Chronic Diseases such as cardiovascular disorders, cancer, diabetes, and many more also are the major consumers of the drugs in the country. In the last few years, due to the growing healthcare innovations, the life expectancy age has increased. Due to this, the population of old age people is rising in China. Furthermore, the rising number of patients with chronic diseases has also boosted the demand for drug delivery in China in the last few years. This is expected to grow during the forecast period. Chronic diseases have led to a rise in the use of injectable drug delivery devices, primarily disposable syringes. The market has seen strategic developments in manufacturing injectable devices, with pharmaceutical companies developing insulin using pens and auto-injectors for patient convenience. Injectable delivery is commonly used for drugs with poor oral bioavailability, targeted systems, and at the site of action. It is used in conditions like cystic fibrosis, hemophilia, autoimmune diseases, pain, hormonal imbalance, Wilson's disease, hepatitis C, and ribose-5-phosphate isomerase deficiency. Injectable drug delivery devices are the second most operating technology after oral drug administration.

MARKET DRIVER:

Increasing Prevalence of diseases

China has been the most populated country in the world for the last many years. Due to this, currently, the population of the old age group has also increased and is projected to rise in upcoming years as well. In 2020, as per the report by the World Bank, the total population of the age group 64 years and above was 168 million, which is an 11.9% rise from 2019. This increasing aging population is one of the key factors driving the drug delivery market in China. As the population of the age group 15 -64 years is also at its peak, hence this will lead to the growth in the aging population in upcoming years. Therefore, this steady growth in the aged population is projected to boost the drug delivery market during the forecast period.

The death rate caused due to non-communicable diseases has been growing over the last decade in the country. As per the World Bank report, there is an increase in 89% of deaths which are caused due to non-communicable diseases in 2019. The non-communicable diseases include chronic diseases such as diabetes, cancer, cardiovascular disorders, chronic kidney diseases, and other diseases such as Alzheimer's, Parkinson and many more. Patients with such diseases require regular prescribed drug delivery daily. Hence, the increase in the number of such individuals in China is a key factor in the growing demand for drug delivery. Which led to the market growth in China's drug delivery market.

Key Developments:

• November 2022- Oyster Point Pharma, a biopharmaceutical company, has been acquired by global healthcare company Viatris Inc. The acquisition is part of Viatris' new ophthalmology franchise, which will focus on developing and commercializing first-in-class pharmaceutical therapies for ophthalmic diseases. The acquisition will be based on Viatris' talented team, the strength of TYRVAYA® Nasal Spray, and Oyster Point Pharma's pipeline. Viatris will initiate a tender offer to purchase all outstanding shares of Oyster Point Pharma for $11.00 per share in cash at closing, plus a contingent value right for a potential cash payment of up to $2.00 per share.
• November 2022- DKSH Business Unit Healthcare has partnered with Nuance Pharma to launch BentrioTM nasal spray in Hong Kong and Macau, marking the first milestone of Nuance Pharma's commercial expansion in the APAC region. The OTC drug-free nasal spray is designed to protect against airborne disease-causing agents, including allergens and viruses. It is marketed in Europe and Asia to help prevent allergic rhinitis and viral infection (including COVID-19). BentrioTM is considered a Class I medical device in the UK and is marketed in Europe, Germany, and Singapore. The product has received 510(k) clearance from the FDA for allergic rhinitis treatment.
• June 2022- EyePoint Pharmaceuticals and OcuMension Therapeutics have received approval from China's NMPA for YUTIQ, a new drug application for treating chronic non-infectious uveitis affecting the posterior segment of the eye. Currently marketed in the U.S., EyePoint maintains development and commercialization rights for YUTIQ in the Americas and Asia.
• Feburary 2022- Insilico Medicine, an AI-driven drug discovery company, has nominated a preclinical candidate compound (PCC) for innovative cancer immunotherapy for its QPCTL program. The first major milestone achieved by Insilico in its strategic collaboration with Fosun Pharma is the development of ISM004-1057D, a small molecule inhibitor targeting QPCTL, a cell surface protein responsible for CD47 pyroglutamate formation. In vivo preclinical studies showed ISM004-1057D to show anti-tumor activity in both liquid and solid tumors, with favourable pharmacokinetics and an acceptable safety profile. Insilico Medicine leverages its Pharma.AI platform to connect biology, chemistry, and clinical trial analysis using next-generation AI systems.

Segmentation

By Type

• Inhalation Drug Delivery
• Injectable Drug Delivery
• Nasal Drug Delivery
• Oral Drug Delivery
• Transdermal Drug Delivery

By Application

• Disease Treatment
• Research/academic purpose